BDX Stock: Why a Spin-Off Changes Earnings

A company can report rising earnings from its ongoing business while its total reported earnings decline. At first glance, those two statements appear contradictory. Yet both can be correct when the company has sold, separated or discontinued part of its operations.

This becomes particularly important after a corporate spin-off. Historical financial statements may be reorganized to distinguish the business that remains from the business that has been separated. Investors comparing earnings across different periods need to understand exactly which operations are included in each number.

Becton, Dickinson and Company (BDX) provides a useful current example. In fiscal 2026, BD reported higher revenue, improving earnings from continuing operations and stronger cash generation. However, its total earnings per share declined substantially compared with the previous year.

The difference is largely explained by the accounting treatment of its former Life Sciences business following a major corporate separation. The lesson extends well beyond medical technology: before interpreting growth, investors need to establish whether they are comparing the same business.

BD became a different company in February 2026

On February 9, 2026, BD completed the separation of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation (WAT).

The transaction was structured as a Reverse Morris Trust, a type of transaction involving the separation of a business followed by its combination with another company, subject to applicable legal and tax requirements.

Under the transaction, BD received approximately $4 billion in cash. BD shareholders received approximately 0.135 Waters shares for each BD share they held on the transaction record date, with cash paid instead of fractional shares.

Following the combination, BD shareholders collectively owned approximately 39.2% of the enlarged Waters business on a fully diluted basis.

BD described the completion in its February 9 transaction announcement.

From an investment perspective, the transaction changed the economic interests held by shareholders. BD became a more focused medical technology business, while shareholders also received an ownership interest in the separated operation through Waters.

That means looking only at BD's current financial results or share price does not necessarily capture the full economic consequences of the separation for someone who owned the shares before the transaction.

Why BD's historical financial statements changed

When a business qualifies for discontinued-operations accounting, its results are presented separately from the company's continuing operations.

The purpose is to help readers distinguish the operations that remain from those that have been disposed of or are being separated.

In BD's November 5 fiscal 2026 earnings release, the company explicitly states that the historical results of its former Biosciences and Diagnostic Solutions business have been classified as discontinued operations for all periods presented.

BD also recast the comparative periods to reflect the reorganized business and reporting structure.

This matters because historical figures originally reported before the separation may not be directly comparable with the continuing-operations figures presented afterward.

For example, comparing the revenue of the old BD group with the revenue of the smaller continuing BD business could create the appearance of a substantial decline, even if the remaining operations were performing well.

Conversely, excluding a poorly performing separated business could make the remaining company's margins or growth appear stronger without requiring a comparable improvement in the underlying operations.

Neither result necessarily indicates misleading accounting. It reflects the fact that the composition of the reporting entity has changed.

BD's earnings tell two different stories

BD's fiscal 2026 results illustrate why investors need to identify the exact earnings measure being discussed.

For the fiscal year ended September 30, 2026, BD reported diluted earnings per share from continuing operations of $5.06, compared with $3.81 in fiscal 2025.

That represents an increase of approximately 33%.

However, total diluted earnings per share, including discontinued operations, declined from $5.82 in fiscal 2025 to $4.09 in fiscal 2026.

That represents a decline of approximately 30%.

Fiscal-year diluted EPS	2025	2026
Continuing operations	$3.81	$5.06
Discontinued operations	$2.00	-$0.97
Total diluted EPS	$5.82	$4.09

The figures may not add precisely because of rounding. They nevertheless demonstrate the difference clearly.

The continuing business generated more earnings per share, while the total company reported lower earnings after the effects of discontinued operations.

This is not a contradiction. These are different earnings bases.

For an investor estimating the future profitability of the remaining BD business, continuing operations generally provide a more relevant starting point than earnings that include a business no longer owned by BD.

However, the discontinued-operations result should not simply be ignored when assessing the historical outcomes of the restructuring. It remains part of the accounting history and may contain economically relevant separation costs, gains or losses.

Continuing earnings growth is not automatically organic growth

Removing discontinued operations improves comparability, but it does not solve every analytical problem.

BD's fiscal 2026 continuing revenue increased 4.9% to $19.46 billion from $18.54 billion in fiscal 2025. Revenue growth adjusted for foreign-exchange effects was approximately 3.9%.

Those are more informative comparisons than mixing the former consolidated group's revenue with the current company's continuing revenue.

Nevertheless, continuing revenue growth is not automatically equivalent to organic growth. Acquisitions, divestitures, product changes and currency movements can still affect the comparison.

Investors should therefore ask several questions before treating an increase as evidence of stronger demand.

Has the comparison period been adjusted for disposed operations? Did the company acquire additional businesses? How much growth came from underlying volume or pricing, and how much resulted from currency movements?

The same discipline applies to earnings. A company may improve earnings because demand increased, because operating expenses declined, because interest costs changed or because restructuring affected the cost base.

The percentage growth rate is only the beginning of the analysis.

The quarterly results show progress in the remaining business

BD's fiscal fourth quarter also provides evidence about the operations that remain.

Revenue increased 5.4% to $5.27 billion from $5.01 billion a year earlier. On a foreign-currency-neutral basis, growth was 5.6%.

The company's four continuing business segments reported different growth rates.

Medical Essentials revenue increased 5.9%, Connected Care increased 1.6%, BioPharma Systems increased 6.5% and Interventional increased 7.6%.

The variation matters because BD is not one uniform medical technology business. Its operations span different products, customers and demand drivers.

A combined growth rate can therefore conceal stronger performance in one business alongside slower development elsewhere.

For investors, evaluating the remaining portfolio requires understanding which segments generate the most revenue, how their margins differ and which businesses are responsible for sustainable earnings growth.

The separation may make those economics easier to study over time, but that does not automatically mean the remaining business will perform better.

Cash flow provides another perspective

BD's continuing operations generated approximately $3.61 billion in operating cash flow during fiscal 2026, compared with $2.77 billion in fiscal 2025.

Capital expenditures associated with continuing operations were approximately $672 million, down from $715 million.

Using the company's definition, free cash flow increased approximately 42.5% to around $2.9 billion.

That development is encouraging because cash generation is relevant to the company's ability to fund investment, service financial obligations and return capital to shareholders.

However, the stronger cash flow should be interpreted alongside the corporate separation.

Historical cash flows must be compared using consistent reporting boundaries, and cash flow from ongoing operations should not be confused with proceeds from disposing of a business.

BD's cash flow statement separately reports approximately $3.92 billion in net financing cash associated with the distribution from the spin-off entity.

That transaction-related cash inflow is fundamentally different from operating cash generated by selling medical technology products and services.

A company can receive substantial cash from a corporate restructuring without the recurring earning power of its remaining operations improving by the same amount.

This distinction becomes particularly important when investors evaluate debt reduction or capital returns following a divestiture.

Shareholders received more than the remaining BD business

A spin-off creates another complication when evaluating historical shareholder returns.

Before the separation, BD shareholders owned an interest in both the businesses that remained and the operations that were subsequently transferred to Waters.

After the transaction, eligible shareholders owned BD shares and received additional Waters shares.

Consequently, the economic return to someone who held BD through the separation cannot be measured accurately by considering only the change in BD's share price without accounting for the distributed Waters shares.

A proper total-return calculation must reflect the value of the securities received, any applicable cash distributions, dividends and the precise measurement dates.

Historical share-price data can also differ depending on whether the data provider adjusts prices for corporate actions.

This is especially relevant when investors compare stock performance with an index or attempt to backtest a strategy through a period containing corporate reorganizations.

Failing to account for the securities distributed could create a misleading picture of the original shareholder's economic outcome.

What MOATEY currently sees in BD

The latest MOATEY assessment provides a separate perspective on BD's longer-term financial characteristics.

As of November 13, 2026, MOATEY classifies BD as a No Grower and assigns a Poor rating with an overall assessment of 6.4 out of 95.

Fundamentals contribute 6.4 out of 65 possible points, with Financial Health at 0.6 out of 15, Growth at 0.9 out of 15, Management at 1.9 out of 15 and Moat at 3 out of 20.

Valuation contributes zero of 30 available points. Importantly, MOATEY's current detailed explanation identifies uncertainty in the valuation estimate and the absence of sufficient evidence under its competitive-advantage criteria. Zero valuation points should therefore not be interpreted as proof that the market price is necessarily excessive.

The historical Growth assessment remains weak. MOATEY's current five-year measures indicate revenue growth of 1.65%, earnings growth of -8.12% and free-cash-flow growth of 1.71%.

These are calculated framework measures, which may differ from the continuing-operations growth figures reported in BD's latest earnings release.

That distinction deserves particular attention after a corporate restructuring. Multi-year assessments can be sensitive to changes in the data used, including the relationship between historical and current reporting boundaries.

The November 12 MOATEY Events also show that BD's Financial Health assessment declined from 11.8 to 0.6 points and its overall score fell from 17.6 to 6.4. The framework's Altman Z-score moved from 2.3 to 1.2.

These are substantial changes in the systematic assessment, but their cause has not been independently established. They should not automatically be attributed to the February spin-off, interpreted as evidence of an unreported corporate event or treated as a standalone prediction of financial distress.

The appropriate analytical response is to investigate the underlying balance-sheet inputs, financial reporting changes and relevant company disclosures before drawing a causal conclusion.

This is one reason MOATEY assessments are most useful as structured evidence for further investigation rather than as unexplained investment signals. The MOATEY factsheet and supporting documentation describe the systematic framework and its underlying research.

What investors should monitor next

The first priority is establishing a clean financial history for the remaining business. That means comparing continuing operations with appropriately recast historical periods, rather than combining financial figures representing different business structures.

Second, investors should monitor the performance of BD's continuing segments. Revenue growth, profitability, product demand and operating expenses will determine whether the more focused portfolio develops stronger economic characteristics.

Third, cash generation should be assessed independently of transaction proceeds. Stronger recurring operating cash flow would provide more convincing evidence of improving financial capacity than a one-time distribution from the separation.

Fourth, the capital structure deserves attention. BD used the transaction to receive substantial cash, and its latest financial statements show changes in debt balances and shareholder distributions. Investors need to assess whether the remaining company has an appropriate financial structure for its operations and expected investment requirements.

Finally, the valuation of the shares must be evaluated using the earnings and cash flows expected from the business that actually remains. Valuation models based on the former group's historical numbers may no longer be appropriate without adjustments.

Always establish which business the numbers describe

BD's fiscal 2026 results illustrate a fundamental principle of financial analysis: growth rates are only meaningful when the underlying comparison is consistent.

The company's earnings from continuing operations increased, while its total earnings per share declined. Both outcomes were reported under the applicable accounting framework, and both contain useful information.

The first helps investors understand the profitability of the operations that remain. The second reflects the broader historical accounting consequences of the corporate separation.

Neither should automatically replace the other.

The spin-off also changed the economic interests held by shareholders, the composition of the remaining business and the financial history relevant to future analysis.

For long-term investors, the correct approach is not simply to choose the most favorable earnings figure. It is to understand the boundaries of the business being measured, separate recurring operating performance from restructuring effects and then determine whether the remaining company can create sustainable shareholder value.

Before asking how quickly a company is growing, make sure the company being measured is still the same one.